Please assess the completion status of the following clinical trial:

Trial Title: Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type 1 Diabetes Mellitus~* 18-46 years of age~* Residual C-peptide production during screening~* Positive for at least one islet autoantibody: insulin (if only insulin autoantibody positive, determination must be within two weeks of insulin initiation), GAD-65, IA-2 or ZnT8~* Positive for at least one gene encoding HLA-DQ8 (DQB\*0302)~* No history of difficult to control hypertension (defined as requiring \> 2 anti-hypertensive medications)~* Agree to intensive management of diabetes with an HgbA1c goal of \< 8.0%~* If female: (a) surgically sterile or (b) postmenopausal or (c) if of reproductive potential, willing to use medically acceptable birth control (e.g. female hormonal contraception, barrier methods or sterilization.) until study completion~* If male and of reproductive potential, willing to use medically acceptable birth control until study completion, unless the female partner is postmenopausal or surgically sterile~Exclusion Criteria:~* Unable or unwilling to comply with the requirements of the study protocol~* No HLA-DQ8 gene (DQB\*0302)~* Difficult to control hypertension (defined as requiring \> 2 anti-hypertensive medications)~* History of postural hypotension or Addison's disease~* Body Mass Index (BMI) \> 30 kg/m2~* Unstable blood sugar control defined as one or more episodes of severe hypoglycemia (defined as hypoglycemia that required the assistance of another person) within the last 30 days~* Administration of an experimental agent for T1D at any time or use of an experimental device for T1D within 30 days of screening, unless approved by the study PI~* History of any organ transplant, including islet cell transplant~* Active autoimmune or immune deficiency disorder (e.g. sarcoidosis, rheumatoid arthritis)~* Anticipated pregnancy during the 12 week study period~* Any social or medical condition that would, in the opinion of the investigator, prevent complete participation in the study or that would pose a significant hazard to the subjects' participation~* History of active substance abuse within 12 months of screening~* A psychiatric or medical disorder that would prevent giving informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 46 Years
- Healthy Volunteers: f

Study Arms:
- Study group (Type: EXPERIMENTAL): All participants selected to continue with Methyldopa administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).